G40.2 G40.3
Conditions
Interventions
Group 1: The assessment of psychiatric problems in patients with epilepsy who switch from levetiracetam to brivaracetam with the examination of the following parameters: SCL-90-S, BDI II, AEP and Qoli
Sponsors
Epilepsiezentrum Kork
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Participants with minimum age of 18 years and a diagnosis of epilepsy according to the 1989 International League Against Epilepsy (ILAE) classification 2. Participants receiving levetiracetam with an unchanged dose within 4 weeks. 3. The decision to switch from levetiracetam to brivaracetam will be made by the physician before and irrespective of his/her decision to include the participant in the study
Exclusion criteria
Exclusion criteria: 1. Participants with known psychogenic non-epileptic seizures 2. Participants had already received brivaracetam in the past 3. Participants with a medical or a psychiatric condition that, in the opinion of the Investigator, could jeopardize or compromise the patient’s own ability to participate in the study: for example patients with status epilepticus, acute psychosis, acute respiratory distress, or participants with significant cognitive disorders etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The aim of this study is to investigate a psychiatric change in epilepsy patients switching from levetiracetam to brivaracetam using the following parameters (Questionnaires): SCL-90-S, BDI II, AEP and Qolie31-P, between June 2020 and June 2021. Participants in the study will fill the questionnaires prior to and 8 days after switching to brivaracetam. | — |
Countries
Germany
Contacts
Public ContactTassanai Intravooth
Epilepsiezentrum Kork
Outcome results
None listed